Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This work presents an optimized protocol to reproducibly immobilize and quantify type I and III collagen onto microplates, followed by an improved in vitro binding assay protocol to study collagen-compound interactions using a time-resolved fluorescence method. The subsequent step-by-step data analysis and data interpretation are provided.

Abstract

Fibrosis occurs in various tissues as a reparative response to injury or damage. If excessive, however, fibrosis can lead to tissue scarring and organ failure, which is associated with high morbidity and mortality. Collagen is a key driver of fibrosis, with type I and type III collagen being the primary types involved in many fibrotic diseases. Unlike conventional protocols used to immobilize other proteins (e.g., elastin, albumin, fibronectin, etc.), comprehensive protocols to reproducibly immobilize different types of collagens in order to produce stable coatings are not readily available. Immobilizing collagen is surprisingly challenging because multiple experimental conditions may affect the efficiency of immobilization, including the type of collagen, the pH, the temperature, and the type of microplate used. Here, a detailed protocol to reproducibly immobilize and quantify type I and III collagens resulting in stable and reproducible gels/films is provided. Furthermore, this work demonstrates how to perform, analyze, and interpret in vitro time-resolved fluorescence binding studies to investigate the interactions between collagens and candidate collagen-binding compounds (e.g., a peptide conjugated to a metal chelate carrying, for example, europium [Eu(III)]). Such an approach can be universally applied to various biomedical applications, including the field of molecular imaging to develop targeted imaging probes, drug development, cell toxicity studies, cell proliferation studies, and immunoassays.

Introduction

The accumulation of fibrous connective tissue as part of the natural wound-healing process following tissue injury is known as fibrosis. However, if the deposition of fibrous tissue fails to terminate and continues beyond what is needed for tissue repair, then fibrosis becomes excessive1,2. Excessive fibrosis impairs organ physiology and function and could lead to organ damage and potentially organ failure3,4,5. Two main drivers of fibrosis are the extracellular matrix (ECM) proteins collagen type I and type III

Protocol

NOTE: All product information used for this work is presented in the Table of Materials.

1. Collagen immobilization

NOTE: Ensure each well in the microplate used during the binding assay has adjacent wells free to avoid cross-fluorescence. Carry out this part of the protocol on ice because collagen self-assembles at rising temperatures and pH levels. Perform this procedure in a tissue culture hood and under sterile conditions because .......

Representative Results

Assessing the stability and concentration of type I and type III collagen immobilized in gels/films
The quantification of the collagen concentration immobilized per well was carried out using three different conditions: a) in wells without washing with PBS after immobilizing the proteins (no wash); b) in wells with a wash step (twice with PBS) after immobilization to remove any uncoated protein; c) in wells after incubation with PBS for 1 h (PBS mimic experiment). The PBS incubation mimicking step .......

Discussion

This work presents a reproducible method for immobilizing type I and type III collagen. It also demonstrates a protocol for acquiring, analyzing, and interpreting in vitro Eu(III) TRF binding data to characterize the binding properties of a candidate ligand toward type I and III collagen. The protocols for immobilizing type I and type III collagen presented here were developed and optimized considering previously published work on type I and type III collagen fibrillogenesis in vitro13.......

Acknowledgements

We are grateful to the following funders for supporting this work: (1) the UK Medical Research Council (MR/N013700/1) and King's College London member of the MRC Doctoral Training Partnership in Biomedical Sciences; (2) BHF program grant RG/20/1/34802; (3) BHF Project grant PG/2019/34897; (4) King's BHF Centre for Research Excellence grant RE/18/2/34213; (5) the ANID Millennium Science Initiative Program - ICN2021_004; and (6) ANID Basal grant FB210024.

....

Materials

NameCompanyCatalog NumberComments
10x PBSGibco14200075Use this to make 1x PBS by diluting in water (1:10)
2M HCLMade in house and details are in the supporting document 
2M Sodium hydroxide +2M GlycineMade in house and details are in the supporting document 
Cell-star 96 well  microplateGreiner Bio-One655 160
DELFIA enhacement solutionPerkin Elmer1244-104
Ice 
Infinite 200 PRO NanoQuant microplate reader TECAN
Non-binding (NBS) 96 well microplates Corning3641
pH electrode Inlab Routine Mettler Toledo 51343050
pH meter (sevenCompact)Mettler Toledo 
Pierce BCA protein assay kit Thermofisher23227
Tissue culture incubator (37 °C, 5% CO2)
Type I bovine collagen, 3 mg/mL Corning354231
Type III human placenta collagen, 0.99 mg/mLAdvanced Biomatrix5021

References

  1. Distler, J. H. W., et al. Review: Frontiers of antifibrotic therapy in systemic sclerosis. Arthritis and Rheumatology. 69 (2), 257-267 (2017).
  2. Wynn, T. A. Fibrotic disease and the TH1/TH2 paradigm. Nature Reviews....

Explore More Articles

Collagen ImmobilizationCollagen Binding AssaysFibrosisType I CollagenType III CollagenSurface CoatingMetal ChelateTime resolved FluorescenceMolecular ImagingDrug DevelopmentCell StudiesImmunoassays

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved